Which patients with stage IV non–small cell lung cancer (NSCLC) may be candidates for treatment with cytotoxic drugs?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print
Answer

Patients with progressive disease and good performance status may be candidates for treatment with single cytotoxic drugs such as docetaxel, pemetrexed, or gemcitabine, if they were not exposed to these drugs in the first-line setting. Selected patients can also be treated with erlotinib, though this is typically used in the third-line setting.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!